Our Governance

Board of Directors

William Huyett

Independent Non-Executive Chairman

William (“Bill”) Huyett was appointed Independent Non-Executive Chairman on 20 September 2018, having served as an Independent Non-Executive Director since 18 June 2017 and having been elected by shareholders at the 2018 AGM. He serves as a member of the Clinical Quality and Safety Committee and the Nominations Committee. He is also Chairman of the Supervisory Board of JSC GHG and is a member of its Clinical Quality and Safety Committee.


Skills and Experience: Mr. Huyett is the Chief Operating Officer of Ironwood Pharmaceuticals a NASDAQ-listed biopharmaceutical innovator in Cambridge, MA. Prior to that, during a 30-year career at McKinsey and Company in the US and Europe, he served clients in health care and other technology-intensive sectors. He advised those clients on value creation strategies and their implications for organization effectiveness and board governance. His areas of expertise include corporate portfolios, growth, M&A and divestitures. He is the co-author of a text on corporate finance: Value: Four Cornerstones of Value Creation. He currently serves on the boards of several not-for-profit institutions, including Rockefeller University in New York and Marine Biological Laboratory in Woods Hole. He is also a non-executive director of Georgia Capital PLC.

Education: Mr Huyett earned a BS in Electrical Engineering and an MBA from the University of Virginia.

Nick Gamkrelidze

Chief Executive Officer

Nikoloz Gamkrelidze was appointed as Chief Executive Officer on 28 August 2015 and was elected by shareholders at the 2016 AGM and re-elected at the 2017 AGM.
He also serves as CEO to JSC GHG and JSC Evex, Deputy Chairman of the Supervisory Board of JSC Evex, and Chairman of the Supervisory Board of JSC Imedi L, as a member of the Supervisory Board of JSC GEPHA and acting chairman of GEPHA.

Skills and Experience: Mr Gamkrelidze was Deputy CEO Finance of BGEO Group PLC from October 2012 to December 2014, and CEO of Insurance Company Aldagi (which included the predecessor companies of GHG Group) from 2007 to 2012. Previously Mr Gamkrelidze served as CEO of My Family Clinic from October 2005 to October 2007. Mr Gamkrelidze was a consultant at the Primary Healthcare Development Project (a World Bank Project) and worked on the development of pharmaceutical policy and regulation in Georgia. Before joining the Primary Healthcare Development Project, he was the Head of the Personal Risks Insurance Department at BCI Insurance Company from 2002 to 2003. Mr Gamkrelidze started his career at the Georgian State Medical Insurance Company in 1998, where he worked for two years. Before joining the Primary Healthcare Development Project, he was the Head of the Personal Risks Insurance Department at BCI Insurance Company from 2002 to 2003. Mr Gamkrelidze started his career at the Georgian State Medical Insurance Company in 1998, where he worked for two years.

Education: Mr Gamkrelidze graduated from the Faculty of General Medicine of Tbilisi with distinctions, and holds an MA in International Healthcare Management from the Imperial College Business School.

David Morisson

Senior Independent Non-Executive Director

David Morrison was appointed as the Senior Independent Non-Executive Director on 4 September 2015 and was elected by shareholders at the 2016 AGM and was re-elected by shareholders at the 2017 AGM. He also serves as Chairman of the Audit Committee and as a member of the Nomination Committee and the Remuneration Committee. Mr Morrison serves as a member of the Supervisory Board of JSC GHG and of its Audit, Nomination and Remuneration Committees.

Skills and Experience: Mr Morrison is a member of the New York bar and worked for 28 years at Sullivan & Cromwell LLP until he withdrew from the firm in 2007 to pursue his other interests. At Sullivan & Cromwell, he served as Managing Partner of the firm’s Continental European offices. His practice focused on advising public companies in a transactional context, from capital raisings and IPOs to mergers and acquisitions. Key clients included investment banks and a wide range of commercial and industrial companies. He advised on a number of the largest privatisations in Europe, and was advisor to Germany’s development bank, Kreditanstalt für Wiederaufbau (KfW), for over 20 years (serving on the board of directors of KfW’s finance subsidiary). Mr Morrison is the author of several publications on securities-law-related topics, and has been recognised as a leading lawyer in Germany and France. In 2008, Mr Morrison turned his attention to financing for nature protection. He became the Founding CEO of the Caucasus Nature Fund (“CNF”), a charitable trust fund dedicated to nature conservation in Georgia, Armenia and Azerbaijan. He resigned as CEO in March of 2016 and now serves on its board of directors as well as on the boards of two new conservation trusts funds he helped to create in 2015 and 2016. Mr Morrison is a non-executive director of Georgia Capital plc.

Education: Mr Morrison received his undergraduate degree from Yale College, received his law degree from the University of California at Los Angeles and was a Fulbright scholar at the University of Frankfurt.

Irakli Gilauri

Non-Executive Director

Irakli Gilauri joined the Board, initially as Chairman, on 4 September 2015 and was elected as a Non-Executive Director by shareholders at the 2016 AGM and re-elected by shareholders at the 2017 and 2018 AGMs. He is a member of the Nomination Committee. Mr Gilauri is also a member of the Supervisory Board of JSC GHG and serves as Chairman of the Supervisory Board of JSC Evex.


Skills and Experience: Mr Gilauri was Chief Executive Officer of BGEO Group PLC from 2011 to May 2018, and was appointed Chairman of Bank of Georgia in September 2015 having previously served as Chief Executive Officer of the Bank since May 2006.  Mr Gilauri joined Bank of Georgia as Chief Financial Officer in 2004. Before his employment with Bank of Georgia, Mr Gilauri was a banker at the EBRD’s Tbilisi and London offices for five years. He currently serves as CEO and on the Supervisory Board of JSC Georgia Capital Group. Mr Gilauri is also an Executive Director, as CEO and Chairman, of Georgia Capital plc.  

Education: Mr Gilauri received his undergraduate degree in Business Studies, Economics and Finance from the University of Limerick, Ireland, in 1998. He was later awarded the Chevening Scholarship, granted by the British Council, to study at the Cass Business School of City University, London, where he obtained his MSc in Banking and International Finance.

Mike Anderson

Independent Non-Executive Director

Mike Anderson was appointed as an Independent Non-Executive Director on 4 September 2015 and was elected by shareholders at the 2016 AGM and re-elected at the 2017 AGM. He serves as Chairman of the Clinical Quality and Safety Committee and as a member of the Nomination Committee. Dr Anderson also serves as a member of the Supervisory Board of JSC GHG and of its Nomination and Clinical Quality and Safety Committees.

Skills and Experience: Dr Anderson was initially appointed as a physician at West Middlesex University Hospital in 1990. He subsequently became a medical manager and joined the board of West Middlesex University NHS Trust as Medical Director in 2003. He served as a medical director at Chelsea and Westminster Hospital from 2003 to 2015, as well as continuing in his role as a physician. Dr Anderson was one of the medical directors for the North West London reconfiguration programme (Shaping a Healthier Future) and continues as a physician at Chelsea and Westminster Hospital and in private medical practice. Dr Anderson has also worked as a clinical advisor and has been chairman of hospital inspections for the Care Quality Commission. Dr Anderson is an honorary clinical senior lecturer at Imperial College of Science, Technology and Medicine and a member of the British Society of Gastroenterology and the British Association for the Study of the Liver.

Education: Dr Anderson undertook his undergraduate medical training at St Bartholomew’s Hospital in London. After general medical training and completion of his MRCP (Member of the Royal College of Physicians), he trained in gastroenterology and general medicine and completed his MD in aspects of viral hepatitis.

Tim Elsigood

Independent Non-Executive Director

Tim Elsigood was appointed as an Independent Non-Executive Director on 4 September 2015 and was elected by shareholders at the 2016 AGM and re-elected at the 2017 AGM. He serves as Chairman of the Remuneration Committee and as a member of the Audit Committee, the Clinical Quality and Safety Committee and the Nomination Committee. Mr Elsigood is also a member of the Supervisory Board of JSC GHG and of its Remuneration, Audit and Clinical Quality and Safety Committees.


Skills and Experience: Mr Elsigood has over 35 years of international healthcare management experience in over 15 countries across the world. He is also currently an Independent Director of Avivo Group, based in Dubai, covering the UAE and Kuwait. The Group has a broad range of healthcare facilities and products. Until 2016 he was a Consultant Advisor to Abraaj in Egypt, Tunisia and Morocco as they expanded their healthcare operations in these countries. Prior to his role in North Africa, Mr Elsigood carried out an extensive review of a major medical diagnostics business in India, evaluating the existing business and advising potential investors on the best path to follow to expand the business and build on the existing portfolio. Before this, he was Vice President for Medsi Group, a private hospital group in Russia. Prior to this, Mr Elsigood worked in Kiev, Ukraine where he was Chief Executive Officer of Isida Hospital, a specialist maternity and women’s hospital with a large IVF centre. He has also carried out executive healthcare roles in Romania and Greece. Initially, Mr Elsigood started his career in the UK National Health Service and after 15 years moved to the private sector in the UK. He then became Senior Vice President of business development in Capio AB, based in Sweden. Mr Elsigood has also served as the UK Head of Alliance Medical Ltd, the largest medical imaging company in Europe.

Education: Mr Elsigood holds an MBA with a focus on health policy and strategy.

Ingeborg Oie

Independent Non-Executive Director

Ingeborg Oie was appointed as an Independent Non-Executive Director on 4 September 2015 and was elected by shareholders at the 2016 AGM and re-elected at the 2017 and 2018 AGMs. She serves as Chairman of the Nomination Committee and is a member of both the Remuneration Committee and the Audit Committee. Ms Oie is also a member of the Supervisory Board of JSC GHG and of its Audit and Remuneration Committees.


Skills and Experience: Ms Oie is Head of Investor Relations at Smith & Nephew, the global medical technology company listed on the London Stock Exchange. Prior to joining Smith & Nephew in 2014, she was a research analyst and managing director at Jefferies, the global investment banking firm, covering the Medical Device and Healthcare Services sectors in Europe, the Middle East and Africa. Her focus spanned European and Middle Eastern hospitals as well as the orthopaedics, dialysis, cardiovascular, hearing aids, drug delivery and dental sectors. She commenced her career at Goldman Sachs in London as an analyst in the Global Investment Research division.

Education: Ms Oie graduated with a first class honours degree in Biomedical Engineering from Imperial College London and completed an MSc in Public Health at the London School of Hygiene and Tropical Medicine. She is a CFA charter holder.

Jacques Richier

Independent Non-Executive Director

Jacques Richier was appointed as an Independent Non-Executive Director on 4 September 2015 and was elected by shareholders at the 2016 AGM and re-elected at the 2017 AGM. He serves as a member of both the Audit Committee and the Nomination Committee. Mr Richier also serves as a member of the Supervisory Board of JSC GHG and of its Audit and Nomination Committees.

Skills and Experience: Mr Richier began his career in the oil industry (Coflexip). He then joined the insurance business in 1985, joining AZUR, a mutual insurance company, where he was the IT and organisation manager before being appointed Chairman and Chief Executive Officer in 1998. In 2000, he joined Swiss Life France as Chief Executive Officer, becoming Chairman and Chief Executive Officer in 2003. In 2008, he was offered the position of Chief Executive Officer of AGF and, in 2010, he became Chairman and Chief Executive Officer of Allianz France. Since 2014, he has also served as Chairman of Allianz WorldWide Partners.

Education: Mr Richier holds a postgraduate degree in Physics from INSA (French National Institute of Applied Science). After being offered a visiting scholar position by the Lawrence Berkeley National Laboratory in Biophysics, California (United States), he received his MBA from HEC (Paris) in 1984.

Caroline Brown

Advisor to the Board; Member of the Audit Committee

Caroline Brown was appointed as an advisor to the Board and a member of the Audit Committee from 24 February 2018.

Skills and Experience: Dr Brown has managed divisions of FTSE100 groups and AIM businesses with international industrial and technology operations and has worked as a corporate finance adviser to governments and corporations with Merrill Lynch, UBS and HSBC. She has chaired audit committees of listed companies for the past 15 years and is a Fellow of the Chartered Institute of Management Accountants. Dr Brown currently serves as an independent Non-Executive Director, and audit chair on the boards of several London quoted companies.  She is a director of Luceco PLC, Earthport PLC, Hydrodec Group PLC, LB-Shell PLC and Gray’s Inn Mansion Limited. Dr Brown is a non-executive director of Georgia Capital plc. She also serves on the MBA Advisory Board of the Cass Business School, University of London.

Education: Dr Brown holds a first-class degree and PhD in Natural Sciences from the University of Cambridge and a Masters of Business Administration from the Cass Business School, University of London.

Fabian Blank

Independent Non-Executive Director

Fabian Blank was appointed as an Independent Non-executive Director on 20 September 2018. He has also been appointed as a member of the Clinical Quality and Safety Committee and the Nomination Committee. Mr Blank was also appointed as a member of the Supervisory Board of JSC GHG and of its Clinical Quality and Safety Committee.

Skills and Experience: Mr. Blank is an entrepreneur, investor and senior management advisor in healthcare. He has operational leadership experience in healthcare services, and a strong background in digital health and technology. Mr. Blank is an early stage investor and founder in digital health, actively involved in a portfolio of patient-centric startups. As an independent senior management and board-level advisor, he works with healthcare providers and payors, medical technology companies, and private equity firms looking at growth opportunities in healthcare including digital transformation, innovation / disruption, and M&A. Previously, Mr. Blank was co-owner and CEO of a midsized rehab clinic group focused on post acute treatment in orthopedics and cardiology. He grew utilisation, revenues, and EBITDA in a mature, highly competitive market before exiting the firm to a private equity group. He started his career at McKinsey & Company, Inc. Throughout his 13 years and as a Partner, he focused on growth topics and consumer centric functions in mobile telecoms and healthcare services. He spent the majority of his time in high growth markets, working in more than 20 countries across Eastern Europe, Sub Saharan Africa, India and South East Asia. 

Education: Mr Blank holds a graduate degree in business management (Diplom Kaufmann) from HHL-Leipzig Graduate School of Management, with semesters at Barcelona's ESADE and Boston University's School of Management. He obtained his intermediate business diploma (Vordiplom) from University of Trier.